Drugs / 89Zr-Df-crefmirlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05849467 | Oct 2023 → Apr 2030 expected | multiple sclerosis, progressive multifocal leukoencephalopathy | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-Df-crefmirlimab | “89Zr-Df-crefmirlimab, an investigational, intravenous PET tracer” NCT05849467 ↗ |
| Modality | Diagnostic / imaging agent | “an investigational, intravenous PET tracer” NCT05849467 ↗ |
| Route | Intravenous | “intravenous injection of anti-CD8 minibody” NCT05849467 ↗ |